Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Investigating the Effect of Lu AG09222 on PACAP38- and VIP-induced Vasodilation, Heart Rate Increase, and Headache in Healthy Subjects

Next Previous
X
Search
Trial Profile

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Investigating the Effect of Lu AG09222 on PACAP38- and VIP-induced Vasodilation, Heart Rate Increase, and Headache in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LU AG09222 (Primary)
  • Indications Headache; Migraine
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 14 Sep 2023 According to H. Lundbeck A/S media release, the company announced the data from this study at the International Headache Congress (IHC) 2023 in Seoul, Korea.
    • 17 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 11 Nov 2021 Planned End Date changed from 10 Dec 2021 to 3 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top